Form 4: Regeneron Executive Joseph LaRosa Reports Stock Transactions

Regeneron Pharmaceuticals EVP General Counsel and Secretary Joseph J. LaRosa reported the acquisition of restricted stock and stock options, alongside a sale of shares for tax withholding purposes.

Summary

• Joseph J. LaRosa, EVP General Counsel and Secretary of Regeneron Pharmaceuticals, Inc. (REGN), reported transactions involving company securities.
• On December 5, 2025, LaRosa acquired 2,476 shares of Common Stock as a Restricted Stock Award under the Second Amended and Restated 2014 Long-Term Incentive Plan.
• These restricted shares vest 50% on December 5, 2027, and the remaining 50% on December 5, 2029.
• Also on December 5, 2025, LaRosa was granted 12,210 Non-Qualified Stock Options with an exercise price of $726.71.
• These stock options vest in four equal annual installments, commencing one year after the grant date (December 5, 2026), and expire on December 5, 2035.
• On December 8, 2025, LaRosa disposed of 1,396 shares of Common Stock at a price of $712.94 per share, primarily for tax withholding related to the awards.
• Following these transactions, LaRosa directly beneficially owns 29,517 shares of Common Stock and 12,210 Non-Qualified Stock Options.
• Indirect beneficial ownership includes 3,402 shares via a 2024 GRAT, 9,000 shares via a 2025 GRAT, and 396 shares via a 401(k) Plan.

Sentiment

Score: 5

Explanation: This is a routine Form 4 filing detailing insider transactions, which typically does not carry a strong positive or negative sentiment. The acquisition of new equity awards is generally positive for aligning management interests, while the sale for tax withholding is a standard practice.

Positives

• Joseph J. LaRosa received a grant of 2,476 shares of Restricted Stock, aligning his interests with long-term company performance.
• LaRosa was awarded 12,210 Non-Qualified Stock Options, providing potential future upside based on stock price appreciation.

Negatives

• Joseph J. LaRosa disposed of 1,396 shares of Common Stock for tax withholding purposes, reducing his direct beneficial ownership.

Future Outlook

The vesting schedules for the restricted stock and stock options indicate future ownership milestones for the reporting person, aligning executive incentives with long-term company performance over several years.

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership of Common Stock through a 2024 GRAT (3,402 shares) and a 2025 GRAT (9,000 shares).

Stakeholder Impact

• Shareholders: The transactions represent routine equity compensation and tax-related sales by a key executive, which is a common practice and generally has minimal direct impact on the broader shareholder base.
• Employees: The equity awards are part of the company's long-term incentive plan, which can serve as a model for executive compensation structures.

Next Steps

• Vesting of 50% of Restricted Stock Award on December 5, 2027.
• Vesting of remaining 50% of Restricted Stock Award on December 5, 2029.
• Annual vesting of Non-Qualified Stock Options over four years, commencing December 5, 2026.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Joseph LaRosa, Insider Transaction, Form 4, Restricted Stock, Stock Options, Equity Compensation